---
phase: 30-eye-safety-ledger-and-closeout
reviewed: "2026-07-13T09:19:00Z"
depth: standard
files_reviewed: 9
files_reviewed_list:
  - BeautySDK/Sources/BeautyCore/Models/BeautyParameters.swift
  - BeautySDK/Sources/BeautyEffects/Planning/BeautyEffectResolver.swift
  - BeautySDK/Tests/BeautyCoreTests/BeautyParametersTests.swift
  - BeautySDK/Tests/BeautyEffectsTests/BeautyEffectResolverTests.swift
  - BeautySDK/Tests/BeautyEffectsTests/EyeWarpProviderTests.swift
  - BeautySDK/Tests/BeautyEffectsTests/MissingLandmarkDegradationTests.swift
  - BeautySDK/Tests/BeautyEffectsTests/FaceShapeWarpProviderTests.swift
  - BeautySDK/Tests/BeautyCoreTests/BeautyEngineGeometryFacadeTests.swift
  - BeautySDK/Tests/BeautyEffectsTests/CombinedEffectSafetyTests.swift
findings:
  critical: 0
  warning: 0
  info: 0
  total: 0
status: clean
---

# Phase 30 Code Review

## Summary

The Phase 30 implementation and requested tests are clean at standard depth for correctness, regressions, security/privacy, test quality, and code quality.

## Review Results

- Public normalization matches positive-only size/tail and signed distance/vertical semantics without changing the 31-field model.
- Resolver cap families, warning/count behavior, and negative no-op behavior match the locked contract.
- Missing, reused, and stale eye geometry skip and zero all eye strengths while non-eye reuse remains scaled by 0.5.
- Fixed warning messages and aggregate metrics expose no eye-side or raw geometry payload.
- Public no-face evidence preserves extent and safe color/filter processing.
- Six direction-specific combined cases and the all-eye case exercise the existing conflict resolver without changing its math.
- Tests assert observable behavior and exact safety outcomes; no contradictory reused-eye-active assertion remains.

## Findings

None.

## Verification

The requested nine-file scope was inspected line by line. A combined focused test invocation covering all seven affected XCTest suites passed 62 tests with zero failures on 2026-07-13. The broader Phase 30 command evidence remains recorded in `30-EYE-SAFETY-EVIDENCE.md`.

## Residual Scope

Device evidence, commercial visual review, broader parity, packaging, and milestone audit remain outside this source/test review.
